279 related articles for article (PubMed ID: 35386387)
21. Epidemiological Patterns of Cannabis- and Substance- Related Congenital Uronephrological Anomalies in Europe: Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36360648
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid and substance relationships of European congenital anomaly patterns: a space-time panel regression and causal inferential study.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvab015. PubMed ID: 35145760
[TBL] [Abstract][Full Text] [Related]
23. Raman-Based Differentiation of Hemp, Cannabidiol-Rich Hemp, and Cannabis.
Sanchez L; Baltensperger D; Kurouski D
Anal Chem; 2020 Jun; 92(11):7733-7737. PubMed ID: 32401504
[TBL] [Abstract][Full Text] [Related]
24. European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Neurological Anomalies: Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612763
[TBL] [Abstract][Full Text] [Related]
25. Geospatiotemporal and Causal Inferential Study of European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Orofacial Anomalies.
Reece AS; Hulse GK
J Xenobiot; 2023 Feb; 13(1):42-74. PubMed ID: 36810431
[TBL] [Abstract][Full Text] [Related]
26. Determination of cannabinoids in hair: Indicators for illegal vs CBD-rich cannabis use.
Casati S; Angeli I; Bergamaschi RF; Ravelli A; Colombo G; Binelli G; Minoli M; Orioli M
Forensic Sci Int; 2022 Apr; 333():111237. PubMed ID: 35228140
[TBL] [Abstract][Full Text] [Related]
27. CBG, CBD, Δ9-THC, CBN, CBGA, CBDA and Δ9-THCA as antioxidant agents and their intervention abilities in antioxidant action.
Dawidowicz AL; Olszowy-Tomczyk M; Typek R
Fitoterapia; 2021 Jul; 152():104915. PubMed ID: 33964342
[TBL] [Abstract][Full Text] [Related]
28. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development.
Reece AS; Hulse GK
Sci Rep; 2021 Jul; 11(1):13892. PubMed ID: 34230557
[TBL] [Abstract][Full Text] [Related]
29. Determination of 11 Cannabinoids in Biomass and Extracts of Different Varieties of Cannabis Using High-Performance Liquid Chromatography.
Gul W; Gul SW; Radwan MM; Wanas AS; Mehmedic Z; Khan II; Sharaf MH; ElSohly MA
J AOAC Int; 2015; 98(6):1523-8. PubMed ID: 26651563
[TBL] [Abstract][Full Text] [Related]
30. Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.
Huestis MA; Sempio C; Newmeyer MN; Andersson M; Barnes AJ; Abulseoud OA; Blount BC; Schroeder J; Smith ML
J Anal Toxicol; 2020 Oct; 44(7):651-660. PubMed ID: 32369162
[TBL] [Abstract][Full Text] [Related]
31. Patterns of Cannabis- and Substance-Related Congenital General Anomalies in Europe: A Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Pediatr Rep; 2023 Feb; 15(1):69-118. PubMed ID: 36810339
[TBL] [Abstract][Full Text] [Related]
32. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
33. Broad Spectrum epidemiological contribution of cannabis and other substances to the teratological profile of northern New South Wales: geospatial and causal inference analysis.
Reece AS; Hulse GK
BMC Pharmacol Toxicol; 2020 Nov; 21(1):75. PubMed ID: 33183341
[TBL] [Abstract][Full Text] [Related]
34. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Niesink RJ; Rigter S; Koeter MW; Brunt TM
Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
[TBL] [Abstract][Full Text] [Related]
35. THC and CBD effects on alcohol use among alcohol and cannabis co-users.
Karoly HC; Mueller RL; Andrade CC; Hutchison KE
Psychol Addict Behav; 2021 Sep; 35(6):749-759. PubMed ID: 33764086
[TBL] [Abstract][Full Text] [Related]
36. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S
Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000
[TBL] [Abstract][Full Text] [Related]
37. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids in clinical practice.
Williamson EM; Evans FJ
Drugs; 2000 Dec; 60(6):1303-14. PubMed ID: 11152013
[TBL] [Abstract][Full Text] [Related]
39. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
40. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
